As a matter of editorial policy, we avoid doing anything that people would interpret as collusion with a commercial company to draw attention to their product. In the case of Rosenstock and colleagues' paper (1), we knew that the FDA had not yet approved inhaled insulin, but we had no idea when it would announce its decision. We could not and did not engineer the publication date to coincide with the FDA announcement.